

CEP Magazine - November 2020 DUSA Pharmaceuticals fined \$20.75 million for fudging dosage requirements

By Sascha Matuszak

The U.S. Department of Justice and DUSA Pharmaceuticals Inc. (DUSA) agreed to settle False Claims Act allegations through a fine and a corporate integrity agreement that requires DUSA to implement reviews and procedures to prevent similar problems in the future.

This document is only available to members. Please log in or become a member.

Become a Member Login

Copyright © 2024 by Society of Corporate Compliance and Ethics (SCCE) & Health Care Compliance Association (HCCA). No claim to original US Government works. All rights reserved. Usage is governed under this website's <u>Terms of Use</u>.